Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Recurrence 1Neoplasm Metastasis 1Delirium 1

Interventions

Specimen Handling 43pembrolizumab 42Biopsy 36Magnetic Resonance Spectroscopy 34Paclitaxel 21Carboplatin 21Gemcitabine 20Nivolumab 19Irinotecan 17Radiosurgery 15Cisplatin 13Taxes 11Pemetrexed 11Ipilimumab 11Fluorouracil 11Cetuximab 11130-nm albumin-bound paclitaxel 11trastuzumab deruxtecan 10olaparib 10Leucovorin 10Capecitabine 10abemaciclib 9Oxaliplatin 9Cyclophosphamide 9Bevacizumab 9palbociclib 8durvalumab 8Fulvestrant 8X-Rays 7Trastuzumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Haloperidol × 90 days × Clear all
NCT03021486 2026-03-18

Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer

M.D. Anderson Cancer Center

Phase 2/3 Active not recruiting
70 enrolled 20 charts

Delirium, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡